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The fully differentiated human melanocyte functions ,as' a 
necessary and integral part of the epidermis, synthesizing 
melanin in intracellular organelles and transferring these 
pigment-containing organelles to surrounding keratino­
eytes. The epidermal environment contains multiple inflam­
matory mediators, cytokines, and growth factors that may 
alter constitutive melanocyte function. Constitutive melano­
cyte function can also be markedly altered by release of such 
mediators in inflammatory dermatoses. Many of the same 
T he human melanocyte resides at the epidermal-dermal junction, where it functions as a highly differentiated cell that produces and transfers melanin in specialized organelles to surrounding keratinocytes. This associa­tion between a melanocyte and a grouy' of keratino­
cytes has been termed the epidermal melanin unit [1 . The epider­
mal melanin unit is dynamic and highly responsive to endogenous 
and exogenous stimuli. There is complex communication between 
the melanocyte, its corresponding keratinocytes, and the surround­
ing epidermal environment that determines the constitutive level of 
melanocyte function. Processes that modify this baseline relation­
ship can alter not only melanocyte pigment production, but also 
melanocyte proliferation, differentiation, immunologic susceptibil­
ity, cytotoxicity, production of inflammatory mediators, cytokines 
and matrix proteins, and cell movement. 
The clinical practice of dermatology provides many instances 
including inflammatory dermatoses, ultraviolet radiation (UVR), 
and psoralen + ultraviolet A (PUV A) treatment where inflamma-
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bFGF: basic fibroblast growth factor 
H8: N-[2-(methyl-amino)-etbyl]-S-isoquinolinesulfonamide dyhy-
drochloride 
lCAM-l: intercellular adhesion molecule-l 
IL: interleukin 
INF-,,: interferon-" 
LFA-l: leukocyte function associated antigen-l 
LT: leukotriene 
MHC: major histocompatibility complex 
NK: natural killer 
PG: prostaglandin 
PICA: protein kinase A 
PUV A: psoralens plus ultraviolet A radiation 
TNF: tumor necrosis factor 
12-HETE: 12-hyciroxy-eicosatetraenoic acid 
UVR: ultraviolet radiation 
factors can also be released by ultraviolet radiation and 
psoralen + ultraviolet A treatment. These inflammatory me­
diators and cytokines affect not only melanocyte pigment 
production, but also proliferation, differentiation, immuno­
logic susceptibility and cytotoxicity, inflammatory mediator, 
cytokine and matrix protein production, and cell movement. 
The effect of inflammatory mediators and cytokines on 
melanocytes and the regulation of these effects are an active 
area of investigation.JlnvestDermatoI100:191S-195S,1993 
tion has profound effects on melanocyte function. It has been pro­
posed by Nordlund that inflammatory mediators and cytokines re­
leased during inflammation are important signals in control of the 
melanocytic response to inflanuliatory dermatoses, UVR, and 
PUV A [2,3]. As this concept has become more accepted as an im­
portant aspect of pigment cell biology, further study of the scope 
and specificity of the effects of many of these compounds on melano­
cyte function has become an active area of investigation. This 
review will discuss the known effects of various inflammatory medi­
ators and cytokines on melanocyte growth, pigmentation, differen­
tiation, immunologic susceptibility, cytotoxicity, production of in­
flammatory mediators, cytokines and matrix proteins, and cell 
movement (Table I). 
PIGMENTATION 
The most common and the most clinically recognizable effect of 
inflammation on pigmentation is alteration in pigment production. 
Clinically, this may present as either hypopigmentation or hyper­
pigmentation. Post-inflammatory hypopigmentation and hyper­
pigmentation are found in many inflammatory skin diseases, and are 
expected components of any dermatitis with junctional inflamma­
tion. One of the most intriguing unanswered questions regarding 
post-inflammatory pigmentary changes is what controls the devel­
opment of hypo pigmentation versus hyperpigmentation. Total epi­
dermal pigment production is related to individual melanocyte pig­
ment production, to the number of functioning pigment cells, and 
to the transfer of pigment to keratinocytes. 
A number of iDflammatory mediators and cytokines have been 
demonstrated to directly affect melanocyte pigment production. 
One of the first groups of inflammatory mediators investigated for 
their effect on melanocyte function were the eicosanoids. Eicosa­
noids are membrane-derived inflammatory mediators that are me­
tabolites of arachidonic acid. Elevated eicosanoid levels have been 
demonstrated in the skin following sunburn [4,5] and during acute 
inflammation associated with atopic dermatitis [6], contact dermati­
tis [7], and psoriasis [8], as well as in urticaria pigmentosa [9]. The 
elevation of these compounds during inflammatory conditions as-
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sociated with hyperpigmentation led to the investigation of their 
direct effect on melanocyte pigment production. The eicosanoids 
that have been studied in greatest detail in relation to melanocyte 
pigment production are prostaglandin D2 (PGD2), PGEa, leuko­
triene C4 (LTC4), and LTB4. LTB4 has been demonstrated to di­
rectly stimulate individual human melanocyte pigment production 
[10]. PGD2 and Ea enhance melanogenesis in the mouse [11] and 
alter the configuration of human melanocytes to a shape simulating 
activation following UVR [12], but there is debate as to their direct 
effect on human melanocyte pigment production. L TC4 also alters 
melanocyte configuration in a manner similar to the prostaglandins, 
but in tissue culture L TC4 causes rapid melanocyte proliferation and 
a marked decrease in pigment production per cell [10,13]. 
Endothelins are vasoconstrictive peptides with a variety of actions 
on many cell types. Recently, endothelins have been shown to have 
specific receptor binding sites on melanocytes and to enhance 
human melanogenesis [14]. Endothelins are also produced by 
human keratinocytes [15] and their release from human keratino­
cytes is increased following UVR [16]. 
Interleukin 1 (IL-l) and IL-6, and tumor necrosis factor-alpha 
(TNF-a), are cytokines produced during inflammatory dermatoses 
including atopic dermatitis [17], contact dermatitis [18], and sun­
burn [19,22]. They are multifunctional primary cytokines with dif­
fuse biologic effects on many different cell types. Although they are 
produced during the same inflammatory dermatoses as are the 
eicosanoids, they have the opposite effect on pigment production. 
All three cytokines inhibit melanogenesis by human melanocytes 
[23]. It has been postulated that these cytokines may be part of a 
negative feedback loop that counteracts the effect of melanogenic 
stimuli on melanocytes [23]. They may also be important mediators 
of post-inflammatory hypopigmentation. 
It is also known that human keratinocytes in culture produce 
other melanogenic stimulants. These compounds have not been 
fully characterized [24], but as with other keratinocyte-derived mel­
anocyte stimulators, it is likely that their release from keratinocytes 
is enhanced by UVR and during other inflammatory dermatoses. 
Another, as yet not fully characterized, melanogenesis stimulator 
has been demonstrated following the experimental induction of 
contact dermatitis in the guinea pig [25]. 
Thus inflammatory mediators have been demonstrated to di­
rectly effect melanocyte pigment production. They have both stim­
ulatory and inhibitory effects. The site of action of the various 
inflammatory mediators and cytokines on melanocyte pigment pro­
duction and the regulation of their effects on pigment production 
that controls the development of post-inflammatory hypopigmen­
tation or hyperpigmentation remain to be elucidated. 
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GROWTH 
As with melanocyte pigment production, there are inflammatory 
mediators and cytokines that affect melanocyte growth. L TC4 was 
the first inflammatory mediator that was convincingly demon­
strated to be a melanocyte mitogen [26]. LTD4, which is a metabo­
lite of L TC4, is equipotent as a melanocyte mitogen. Endothelin not 
only enhances human melanocyte melanogenesis, but it is also a 
melanocyte mitogen [14]. Only the leukotrienes are effective mela­
nocyte mitogens without the addition of other melanocyte mito­
gens. Other melanocyte mitogens such as basic fibroblast growth 
factor (bFGF) and cholera toxin require the presence of multiple 
mitogens for proliferation. Endothelin requires the addition of chol­
era toxin to maintain melanocyte growth. The mechanism of action 
of these compounds is still debated, but the L TC4 effects appear to 
involve PKA activation, because they are inhibited by the protein 
kinase A inhibitor H8 [10]. LTC4 has also been shown to induce 
c-fos expression in adult human melanocytes [27]. Endothelins trig­
ger an increase in intracellular calcium levels and inositol-l,4,S­
trisphosphate and may stimulate mitogenesis through that second 
messenger pathway [14]. It is unknown if all melanocyte growth 
factors operate through the same final growth regulatory pathway 
or through the stimulation of separate and distinct transcriptional 
activating factors. 
Similar to their effect on melanocyte pigment production 11-1, 
11-6 and TNF-a also inhibit melanocyte proliferation [23]. Again, 
these cytokines, plus L TC4 and endothelin as well as other keratino­
cyte-produced factors, are all released during inflammation, but the 
contribution of each to the eventual increase or decrease in melano­
cyte numbers remains unclear. 
DIFFERENTIATION 
Inflammatory mediators and cytokines not only alter melanocyte 
pigment production and growth, but they can also alter the differ­
entiation state of the melanocyte. If the terminal differentiation 
state of a melanocyte is active pigment production and transfer of 
pigment to keratinocytes, then nevi and melanomas are less differ­
entiated than normal human melanocytes. Alterations of melano­
cyte function that make melanocytes phenotypically more like 
nevus cells or melanomas are then changes to a less differentiated 
state. 
Normal unstimulated human melanocytes do not express major 
histocompatibility complex (MHC) class II antigens [28]. Inter­
feron gamma (IFN-y) induces the expression of MHC class II anti­
gens on human melanocytes [29]. MHC class II antigens are gener­
ally expressed on dysplastic nevi and melanomas and are proposed as 
markers of malignant progression [30]. IFN-y also markedly alters 
cell morphology of normal human melanocytes. IFN-y induces 
cytoplasmic spreading and flattening of melanocytes resulting in a 
phenotype that resembles melanoma cells in culture [31]. 
Other markers of malignant progression and differentiation are 
cell-surface gangliosides. Human melanocytes express GM3 almost 
exclusively, whereas melanomas express high levels of GD3 and 
GM3 [32]. Tumor necrosis factor-alpha (TNF-a) when added to 
melanocytes cultured in phorbol ester-containing media markedly 
enhanced GD3 expression and also altered the appearance of the 
melanocytes much as did IFN-y [32]. Thus cytokines may be in­
volved in the alteration of melanocyte differentiation in the progres­
sion to more malignant phenotypes. 
As well as being a potent stimulus for melanocyte growth, L TC4 
also alters melanocyte differentiation. Adult human melanocytes 
can normally be maintained in tissue culture for a short period of 
time, whereas those grown in media supplemented with LTC, have 
a prolonged life span [27]. Not only are the LTC4-stimulated cells 
capable of prolonged survival, but their differentiation state is al­
tered to the point that they lose their contact inhibition and form 
nevoid-appearing colonies [27]. 
Thus, multiple inflammatory mediators and cytokines function 
in vitro to make melanocytes phenotypically more like nevus cell 
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and melanomas. It is possible that similar changes are important in 
nevus and melanoma development and progression in vivo. 
IMMUNOLOGIC SUSCEPTIBILITY 
AND CYTOTOXICITY 
Melanocytes are susceptible to immunologic damage and killing 
[33]. Immunologic cytotoxicity is a multistage process involving 
effector-target attachment through pairs of adhesion molecules, ac­
tivation of leukocyte receptors by target antigen, and other cell-sur­
face markers and triggering of lysis [34,35]. The interaction of 
intercellular adhesion molecule-l (ICAM-l, CD54) on targets with 
leukocyte function associated antigen-l (LFA-l) on leukocytes is 
one adhesion pair that initiates effector-target interaction in numer­
ous types of MHC-restricted and non-MHC-restricted cytotoxic­
ity: cytotoxic T lymphocyte lysis, antibody-dependent cellular cyto­
toxicity, natural killer (NK), and lymphokine-activated killer lysis 
[34,35]. Expression of cell-surface ICAM-l on melanocytes is in­
duced by IFN-y, TNF-a, TNF-P, IL-l, IL-6, and IL-7 [36,37]. 
Cytokine-enhanced melanocyte ICAM-l expression may trigger 
leukocyte/melanocyte attachments that may be of importance in 
vitiligo, in immune surveillance of malignant transformation of 
melanocytes, and in innocent bystander destruction in inflamma­
tory dermatoses leading to post-inflammatory hypopigmentation. 
Because cell-surface ICAM-l is also a marker of tumor progression 
in melanoma [38], it may have other adhesion functions in trans­
formed melanocytes such as initiating attachment to vascular endo­
thelium as a prelude to metastasis. The alteration of melanocyte 
cell-surface ICAM-l by inflammatory mediators and cytokines is 
also another example of changes in melanocyte differentiation to a 
phenotype more resembling melanoma cells. 
Melanocytes are also highly susceptible to damage by exogenous 
hydrogen peroxide [33] as well as endogenous reactive oxygen spe­
cies. This may largely be due to the quantitative lack of catalase, 
peroxidase, and superoxide dismutase measured in cultured human 
melanocytes compared to cultured human keratinocytes and fibro­
blasts [39]. This lack of defense mechanisms may make the melano­
cyte even more susceptible to reactive oxygen species generated by 
macrophages [40], NK cells [41], and neutrophils [42] during in­
flammatory dermatoses. This may be another mechanism leading to 
melanocyte injury and cytotoxicity. 
INFLAMMATORY MEDIATOR, CYTOKINE, AND 
MATRIX PROTEIN PRODUCTION 
Inflammatory mediators and cytokines can also influence the melan­
ocyte role in affecting its surrounding environment. Melanocytes 
not only are targets during inflammatory dermatoses, but they also 
contribute to the overall inflammatory process. IL-l and TNF-a 
stimulate melanocytes to produce IL-8 and monocyte chemotactic 
and activating factor [43]. Melanocytes are also a source for IL-l 
[44], 12-hete, and LTB. [45]. These inflammatory mediators and 
cytokines are signals for inflammatory cell chemotaxis that further 
enhances the inflammatory!rocess. 
Melanocytes produce an secrete multiple matrix proteins in­
cluding fibronectin and laminin [46]. Melanocyte production of 
fibronectin is enhanced by TNF-a and IFN-y [47]. It has also been 
demonstrated that human melanocyte movement in vitro is en­
hanced by type IV collagen. The production of matrix proteins by 
melanocytes may be important in the alteration of the phenotype 
associated with melanocyte movement from the epidermal-dermal 
junction during nevus formation and in the migration of melano­
cytes from the outer root sheath of the hair follicle to the epidermis 
during the repigmentation of vitiligo. 
MELANOCYTE MOVEMENT 
Melanocyte movement is affected not only by the local production 
of matrix proteins, but is also enhanced by inflammatory mediators 
and cytokines. LTC4 and transforming growth factor-alpha (TGF-
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Figure 1. Potential sources of inflammatory mediators and cytokines 
released during inflammatory dermatoses, UVR, and PUV A that then 
effect melanocyte pigmentation, proliferation, differentiation, immuno­
logic susceptibility and cytotoxicity, inflammatory mediator, cytokine, 
and matrix protein production. 
a) both enhance melanocyte chemokinesis with LTC. being more 
potent and having a longer-lasting effect [48]. LTC4 may play a role 
in the migration of melanocytes from the outer root sheath of hair 
follicles during the repigmentation of vitiligo. It may also influence 
melanocyte movement during nevus formation [27]. 
CONCLUSION 
The melanocyte does not function as an isolated epidermal cell. It is 
intimately associated with human keratinocytes in the epidermal­
melanin unit and is actively influenced by inflammatory mediators 
and cytokines. It also appears to participate in the inflammatory 
response_ When one considers the inter-related effects of inflam­
mation on melanocyte pigmentation, proliferation, differentiation, 
immunologic susceptibility and cytotoxicity, inflammatory media­
tor, cytokine and matrix protein production, and movement, the 
physical relationship of melanocytes in the epidermal environment 
is a major factor. Fig 1 summarizes the relative location of inflamma­
tory mediators, cytokines, and extracellular matrix molecules that 
are released following UVR, PUV A treatment, or inflammatory 
dermatoses. These factors can lead to opposing effects on melano­
cyte growth and pigmentation, to an alteration of differentiation 
markers on melanocytes, to increased immunologic susceptibility 
and cytotoxicity, to melanocyte production of inflammatory media­
tors, cytokines and matrix proteins, as well as to stimulation of 
melanocyte movement from their location in the basal cell zone. 
Interpreting the relative importance of these factors and of the ex­
tracellular matrix molecules of the epidermal-dermal junction on 
melanocyte function in vivo is a major investigative challenge_ The 
regulation of the various responses of melanocytes to inflammatory 
mediators and cytokines and the importance of each response in a 
given situation remain to be identified and clarified. 
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